Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Hematologic Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01369849
What this trial is testing

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT00346255
What this trial is testing

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
ImmunoGen, Inc. 37
Early research (Phase 1)Study completedNCT03143985
What this trial is testing

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Koen van Besien 18
Testing effectiveness (Phase 2)Study completedNCT00051116
What this trial is testing

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene Corporation 100
Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Testing effectiveness (Phase 2)Looking for participantsNCT06644443
What this trial is testing

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Shenzhen University General Hospital 10
Testing effectiveness (Phase 2)UnknownNCT05576532
What this trial is testing

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

Who this might be right for
T-lymphoblastic LymphomaRelapsed DiseaseRefractory Lymphoma+3 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 30
Early research (Phase 1)Study completedNCT00664898
What this trial is testing

The Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 18
Testing effectiveness (Phase 2)Study completedNCT01736943
What this trial is testing

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Who this might be right for
Acute Myelogenous Leukemia
Joseph Tuscano 25
Early research (Phase 1)WithdrawnNCT03752138
What this trial is testing

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Who this might be right for
Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT04139434
What this trial is testing

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Who this might be right for
AML/MDSCMMLRelapse+3 more
Newave Pharmaceutical Inc 32
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Testing effectiveness (Phase 2)Ended earlyNCT01383447
What this trial is testing

Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Who this might be right for
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
National Cancer Institute (NCI) 2
Testing effectiveness (Phase 2)Study completedNCT01088984
What this trial is testing

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia

Who this might be right for
Leukemia
Teva Branded Pharmaceutical Products R&D, Inc. 43
Testing effectiveness (Phase 2)Looking for participantsNCT06561152
What this trial is testing

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Stanford University 20
Early research (Phase 1)Study completedNCT03625505
What this trial is testing

Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
AbbVie 61
Testing effectiveness (Phase 2)Ended earlyNCT00849251
What this trial is testing

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
University of Washington 31
Early research (Phase 1)UnknownNCT04412577
What this trial is testing

TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Who this might be right for
Relapsed/Refractory Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 57
Early research (Phase 1)Ended earlyNCT04045028
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Multiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma
Genentech, Inc. 41
Very early researchUnknownNCT03661554
What this trial is testing

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma
The Pregene (ShenZhen) Biotechnology Company, Ltd. 15
Next Page